KD-6005

N/A

Report date: 2025/04/23 11:19:44

Base Information

Drug NameKD-6005
Drug Alias NameKD6005KD-6005
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibody
Mechanisms of ActionTumor necrosis factor ligand superfamily member 13 modulatorsAnti-Tumor necrosis factor αB-cell activating factor receptor modulators
TargetsTumor necrosis factor ligand superfamily member 13Tumor necrosis factor αB-cell activating factor receptor
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Kanda Bio-Technology Co LtdShanghai Celgen Bio-Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Celgen Bio-Pharmaceutical Co LtdShanghai Kanda Bio-Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A